{"id":58843,"date":"2026-03-05T13:50:23","date_gmt":"2026-03-05T05:50:23","guid":{"rendered":"https:\/\/flcube.com\/?p=58843"},"modified":"2026-03-05T13:50:24","modified_gmt":"2026-03-05T05:50:24","slug":"pyrotech-therapeutics-ptt-936-wins-nmpa-approval-novel-alpk1-agonist-targets-bladder-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58843","title":{"rendered":"Pyrotech Therapeutics&#8217; PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer"},"content":{"rendered":"\n<p><strong>Pyrotech (Beijing) Biotechnology Co., Ltd. (&#8220;Pyrotech Therapeutics&#8221;)<\/strong> announced that its <strong>internally developed small\u2011molecule innate immune agonist PTT-936<\/strong> has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>non\u2011muscle\u2011invasive bladder cancer (NMIBC)<\/strong>. The <strong>novel ALPK1 (Alpha\u2011kinase 1) agonist<\/strong>\u2014already <strong>FDA\u2011cleared for US trials in March\u202f2025<\/strong>\u2014represents a <strong>first\u2011in\u2011class mechanism<\/strong> activating the <strong>body&#8217;s immune system<\/strong> to combat tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Pyrotech (Beijing) Biotechnology Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>PTT-936<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Small\u2011molecule innate immune agonist<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td><strong>ALPK1 (Alpha\u2011kinase 1)<\/strong><\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Novel mechanism; activates innate immune system for anti\u2011tumor response<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA approved (China) \u2013 March\u202f2026; FDA approved (US) \u2013 March\u202f2025<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Non\u2011muscle\u2011invasive bladder cancer (NMIBC)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Model<\/th><th>PTT-936 Result<\/th><\/tr><\/thead><tbody><tr><td><strong>NMIBC Models<\/strong><\/td><td>Excellent efficacy demonstrated<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable preclinical safety<\/td><\/tr><tr><td><strong>Clinical Promise<\/strong><\/td><td>Brand\u2011new therapeutic option for NMIBC patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class ALPK1 Mechanism:<\/strong> PTT-936 is the <strong>world&#8217;s first clinical\u2011stage ALPK1 agonist<\/strong>, positioning Pyrotech as a <strong>pioneer in innate immune activation<\/strong>\u2014a <strong>novel immuno\u2011oncology approach<\/strong> distinct from <strong>checkpoint inhibitors, cytokines, or STING agonists<\/strong>.<\/li>\n\n\n\n<li><strong>NMIBC Unmet Need:<\/strong> <strong>Non\u2011muscle\u2011invasive bladder cancer<\/strong>\u2014comprising <strong>70% of new bladder cancer diagnoses<\/strong>\u2014has <strong>limited effective options<\/strong> beyond <strong>BCG immunotherapy<\/strong> (supply shortages, toxicity) and <strong>intravesical chemotherapy<\/strong>; <strong>ALPK1 activation<\/strong> offers <strong>novel immunotherapy mechanism<\/strong> for <strong>BCG\u2011unresponsive or \u2011intolerant patients<\/strong>.<\/li>\n\n\n\n<li><strong>Dual\u2011Regulatory Validation:<\/strong> <strong>FDA + NMPA approvals<\/strong> within <strong>12 months<\/strong> demonstrate <strong>global regulatory confidence<\/strong> in <strong>ALPK1 mechanism<\/strong> and <strong>PTT-936 safety profile<\/strong>, supporting <strong>parallel China\u2011US development<\/strong> and <strong>multinational partnership attractiveness<\/strong>.<\/li>\n\n\n\n<li><strong>Innate Immune Platform:<\/strong> <strong>ALPK1 agonism<\/strong> may have <strong>broad applicability<\/strong> beyond NMIBC to <strong>other solid tumors<\/strong> where <strong>innate immune activation<\/strong> can <strong>trigger adaptive anti\u2011tumor responses<\/strong>; successful NMIBC trials establish <strong>proof\u2011of\u2011mechanism<\/strong> for <strong>pipeline expansion<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>NMIBC Market Size<\/strong><\/td><td>~\u202f$1.5\u202fbillion globally; BCG shortage creates urgent demand for alternative immunotherapies<\/td><\/tr><tr><td><strong>Bladder Cancer Immunotherapy<\/strong><\/td><td>BCG standard for NMIBC; checkpoint inhibitors (pembrolizumab, atezolizumab) approved for BCG\u2011unresponsive disease; ALPK1 agonism represents novel mechanism<\/td><\/tr><tr><td><strong>Innate Immune Agonist Trend<\/strong><\/td><td>STING agonists faced toxicity challenges; ALPK1 offers alternative innate activation pathway with potentially improved safety<\/td><\/tr><tr><td><strong>China Biotech Innovation<\/strong><\/td><td>Pyrotech&#8217;s dual FDA\/NMPA approvals exemplify <strong>China\u2011origin first\u2011in\u2011class drug development<\/strong>; supports <strong>domestic innovation ecosystem maturation<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase I NMIBC enrollment, ALPK1 target validation in humans, and innate immune activation efficacy. Actual results may differ due to risks including first\u2011in\u2011human safety signals, competitive BCG alternative development, and intravesical delivery optimization challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pyrotech (Beijing) Biotechnology Co., Ltd. (&#8220;Pyrotech Therapeutics&#8221;) announced that its internally developed small\u2011molecule innate immune&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58844,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1892],"class_list":["post-58843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-pyrotech-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pyrotech Therapeutics&#039; PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pyrotech (Beijing) Biotechnology Co., Ltd. (&quot;Pyrotech Therapeutics&quot;) announced that its internally developed small\u2011molecule innate immune agonist PTT-936 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for non\u2011muscle\u2011invasive bladder cancer (NMIBC). The novel ALPK1 (Alpha\u2011kinase 1) agonist\u2014already FDA\u2011cleared for US trials in March\u202f2025\u2014represents a first\u2011in\u2011class mechanism activating the body&#039;s immune system to combat tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58843\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pyrotech Therapeutics&#039; PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"Pyrotech (Beijing) Biotechnology Co., Ltd. (&quot;Pyrotech Therapeutics&quot;) announced that its internally developed small\u2011molecule innate immune agonist PTT-936 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for non\u2011muscle\u2011invasive bladder cancer (NMIBC). The novel ALPK1 (Alpha\u2011kinase 1) agonist\u2014already FDA\u2011cleared for US trials in March\u202f2025\u2014represents a first\u2011in\u2011class mechanism activating the body&#039;s immune system to combat tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58843\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T05:50:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T05:50:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pyrotech Therapeutics&#8217; PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer\",\"datePublished\":\"2026-03-05T05:50:23+00:00\",\"dateModified\":\"2026-03-05T05:50:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843\"},\"wordCount\":425,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0502.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Pyrotech Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58843#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58843\",\"name\":\"Pyrotech Therapeutics' PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0502.webp\",\"datePublished\":\"2026-03-05T05:50:23+00:00\",\"dateModified\":\"2026-03-05T05:50:24+00:00\",\"description\":\"Pyrotech (Beijing) Biotechnology Co., Ltd. (\\\"Pyrotech Therapeutics\\\") announced that its internally developed small\u2011molecule innate immune agonist PTT-936 has received clinical trial approval from China's National Medical Products Administration (NMPA) for non\u2011muscle\u2011invasive bladder cancer (NMIBC). The novel ALPK1 (Alpha\u2011kinase 1) agonist\u2014already FDA\u2011cleared for US trials in March\u202f2025\u2014represents a first\u2011in\u2011class mechanism activating the body's immune system to combat tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58843\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pyrotech Therapeutics' PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58843#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pyrotech Therapeutics&#8217; PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pyrotech Therapeutics' PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Pyrotech (Beijing) Biotechnology Co., Ltd. (\"Pyrotech Therapeutics\") announced that its internally developed small\u2011molecule innate immune agonist PTT-936 has received clinical trial approval from China's National Medical Products Administration (NMPA) for non\u2011muscle\u2011invasive bladder cancer (NMIBC). The novel ALPK1 (Alpha\u2011kinase 1) agonist\u2014already FDA\u2011cleared for US trials in March\u202f2025\u2014represents a first\u2011in\u2011class mechanism activating the body's immune system to combat tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58843","og_locale":"en_US","og_type":"article","og_title":"Pyrotech Therapeutics' PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer","og_description":"Pyrotech (Beijing) Biotechnology Co., Ltd. (\"Pyrotech Therapeutics\") announced that its internally developed small\u2011molecule innate immune agonist PTT-936 has received clinical trial approval from China's National Medical Products Administration (NMPA) for non\u2011muscle\u2011invasive bladder cancer (NMIBC). The novel ALPK1 (Alpha\u2011kinase 1) agonist\u2014already FDA\u2011cleared for US trials in March\u202f2025\u2014represents a first\u2011in\u2011class mechanism activating the body's immune system to combat tumors.","og_url":"https:\/\/flcube.com\/?p=58843","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T05:50:23+00:00","article_modified_time":"2026-03-05T05:50:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58843#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58843"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pyrotech Therapeutics&#8217; PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer","datePublished":"2026-03-05T05:50:23+00:00","dateModified":"2026-03-05T05:50:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58843"},"wordCount":425,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58843#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0502.webp","keywords":["Clinical trial approval \/ initiation","Pyrotech Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58843#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58843","url":"https:\/\/flcube.com\/?p=58843","name":"Pyrotech Therapeutics' PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58843#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58843#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0502.webp","datePublished":"2026-03-05T05:50:23+00:00","dateModified":"2026-03-05T05:50:24+00:00","description":"Pyrotech (Beijing) Biotechnology Co., Ltd. (\"Pyrotech Therapeutics\") announced that its internally developed small\u2011molecule innate immune agonist PTT-936 has received clinical trial approval from China's National Medical Products Administration (NMPA) for non\u2011muscle\u2011invasive bladder cancer (NMIBC). The novel ALPK1 (Alpha\u2011kinase 1) agonist\u2014already FDA\u2011cleared for US trials in March\u202f2025\u2014represents a first\u2011in\u2011class mechanism activating the body's immune system to combat tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58843#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58843"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58843#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0502.webp","width":1080,"height":608,"caption":"Pyrotech Therapeutics' PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58843#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pyrotech Therapeutics&#8217; PTT-936 Wins NMPA Approval \u2013 Novel ALPK1 Agonist Targets Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58843"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58843\/revisions"}],"predecessor-version":[{"id":58845,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58843\/revisions\/58845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58844"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}